Most people think of phenylalanine, if at all, as the warning on a diet soda can. That warning is there for a rare inherited condition, but the blood level of this single amino acid turns out to tell a much broader story. In large studies of adults, a modestly elevated level tracks with mortality in heart failure, critical illness, severe infection, and COVID-19, often independently of the usual risk markers.
That makes Phe (phenylalanine) a useful window into how well your liver, kidneys, and muscle are keeping pace with the daily turnover of protein. A level that drifts upward can signal decompensating metabolism long before standard labs flag anything specific.
Phenylalanine is one of nine essential amino acids, meaning you have to get it from food. Your liver uses an enzyme called PAH (phenylalanine hydroxylase) to convert most of it into tyrosine, which in turn becomes dopamine, adrenaline, and thyroid hormones. Roughly three quarters of the phenylalanine you eat goes through this single pathway.
A normal blood level reflects a balance: you bring it in through food and muscle breakdown, your liver clears it through PAH, and your kidneys handle the byproducts. When any part of that system falters, whether from a genetic enzyme defect, liver stress, kidney dysfunction, inflammation, or accelerated muscle breakdown during illness, phenylalanine rises in the blood.
The classic reason to measure phenylalanine is to detect and monitor phenylketonuria (PKU), a genetic condition where PAH does not work. Without treatment, phenylalanine accumulates to levels that damage the developing brain. Newborn screening in many countries uses a phenylalanine cutoff around 120 micromoles per liter (a unit for small concentrations in blood) to flag the condition early.
In people already diagnosed with PKU, long-term control below 360 micromoles per liter is associated with higher mean IQ than levels above that threshold, and levels above 400 micromoles per liter are linked to lower IQ in young children and worse executive function in older children. For women with PKU who become pregnant, keeping the level at or below 360 micromoles per liter before conception and during pregnancy substantially reduces the risk of congenital heart disease, microcephaly, growth restriction, and intellectual disability in the baby.
In adults without PKU, the most striking finding is that modestly elevated phenylalanine predicts death from heart failure. In 152 patients with severe heart failure, elevated plasma phenylalanine predicted all-cause mortality independently of standard prognostic factors and inflammatory cytokines. A larger cardiac ICU study of 497 patients found that what the authors called stress hyperphenylalaninemia was tied to higher 90-day and one-year mortality, with genetic variants in the BH4 cofactor pathway increasing the risk.
A population study pooling 12,671 participants from the PROSPER and FINRISK 1997 cohorts, using nuclear magnetic resonance-based metabolomics, identified phenylalanine as a novel predictor of first-time heart failure hospitalization in older adults. A large analysis across three cohorts totaling 16,401 participants also flagged phenylalanine as a cardiovascular risk biomarker.
What this means for you: if you already have heart failure or strong cardiovascular risk, a rising phenylalanine is an early signal that the metabolic machinery across your liver, kidneys, and muscle is under strain, and it may prompt a harder look at organ function and treatment optimization.
Phenylalanine metabolism is among the most disrupted pathways in severe infection. In 214 adults with acute respiratory distress syndrome, higher plasma phenylalanine at the onset of illness was independently associated with hospital mortality, suggesting it could serve as an early prognostic metabolic biomarker. In severely ill adults with infection, a phenylalanine level at or above 84 micromoles per liter, alone or combined with low leucine, defined a high-risk metabolic type with much higher mortality.
In COVID-19, serum phenylalanine tracked with disease severity: lower in mild cases and higher in moderate and severe cases, correlating with ICU need and mortality, independently of cytokine levels.
Cutoffs for phenylalanine come mainly from PKU guidelines rather than from general-population preventive medicine. They are usually expressed in micromoles per liter, and the specimen matters: dried blood spot values run roughly 18 to 28 percent lower than plasma values measured by ion-exchange chromatography, so a dried spot reading of 360 micromoles per liter corresponds to roughly 461 micromoles per liter in plasma. The ranges below come from ACMG (American College of Medical Genetics and Genomics) guidance and pooled PKU outcome data, and are illustrative rather than universal population targets.
| Tier | Plasma Range | What It Suggests |
|---|---|---|
| Newborn screening cutoff | Around 120 µmol/L | Level at or above this in a newborn should be investigated for PKU |
| PKU treatment target, ages 0 to 12 | 120 to 360 µmol/L | Range associated with the best cognitive outcomes |
| PKU target, age over 12 | 120 to 600 µmol/L | Wider range used in older patients, based on expert opinion |
| Neurocognitive risk threshold | Above 400 µmol/L | Linked to lower IQ in young children and worse executive function |
| Preconception and pregnancy in PKU | At or below 360 µmol/L | Substantially reduces risk of harm to the baby |
Phenylalanine levels decline slightly across trimesters in healthy pregnancy, with trimester-specific reference ranges available. Compare your results within the same lab over time for the most meaningful trend.
A single phenylalanine measurement carries real noise. In dried blood spots, within-person biological variation is about 9.5 percent, and when you add analytical imprecision, the reference change value, meaning the change needed to be 95 percent confident it is not just random, works out to about 30 percent. At a level of 360 micromoles per liter, that means a shift of more than about 109 micromoles per liter is needed to confirm a real biological change.
Get a baseline, retest in three to six months if you are actively making lifestyle changes or managing a condition that affects metabolism, and at least annually thereafter. If you have PKU, heart failure, or chronic kidney disease, your clinical team may recommend much more frequent checks. The goal is to see the trajectory, not react to a single number.
A single high phenylalanine in an otherwise well adult is rarely diagnostic on its own. Pair it with companion testing to understand what is driving it.
If your result is persistently elevated with liver or kidney findings, a metabolic or internal medicine specialist can help work through the causes. If you have a family history of PKU or a borderline newborn screen, a genetics or inherited metabolic disease clinic is the right destination.
A few things can move your phenylalanine reading without meaning what it looks like they mean.
Evidence-backed interventions that affect your Phenylalanine level
Phenylalanine is best interpreted alongside these tests.